Professor Glenn A. Okun
The Rabid Capitalist: The Big Point is a summary of a detailed note available to paid subscribers.
Sometimes, he or she who invests in a unicorn gets the horn. Chime will be a case in point. Its initial public offering today will leave some high-profile venture capitalists with large losses on a mark-to-market basis.
Complete content is available for a $15 monthly subscription. Click here to subscribe:
The Rabid Capitalist 
Leave a comment